H-1B sponsorship profile: Kiniksa Pharmaceuticals Corp. Across U.S. Department of Labor LCA disclosures, Kiniksa Pharmaceuticals Corp filed 7 Labor Condition Applications covering 7 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (7 certified of 7 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Kiniksa Pharmaceuticals Corp’s H-1B petitions range from $98,000 at the low end to $290,000 at the high end, with a petition-weighted average of $169,385. That range reflects the mix of occupations the company sponsors, led by Senior Director, Global Medical Safety (1 petitions at $290,000 avg), followed by Scientist, Analytical Science & Quality Testing and Manager, Quality Control. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Kiniksa Pharmaceuticals Corp is headquartered in Lexington, MA under NAICS code 3254, and places H-1B workers across 1 state, most heavily in MA. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Kiniksa Pharmaceuticals Corp ranks. By H-1B petition volume, Kiniksa Pharmaceuticals Corp is #21,197 of 119,880 employers nationally and #921 of 5,193 employers headquartered in MA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.